Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in anemic low/int-1 risk MDS
NCT01513317Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2011
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of siltuximab in myelodysplastic syndrome (MDS), sponsored by Janssen Pharmaceutical. Started Nov 2011; status: terminated.
02
Drugs
siltuximab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01513317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513317.